Introduction {#Sec2}
============

46,XY disorders of sex development (46,XY DSD) are clinically and genetically heterogeneous conditions that lead to genital abnormalities at birth, defective sexual development during puberty, and infertility in adulthood \[[@CR1],[@CR2]\]. To date, mutations in several genes have been identified in patients with 46,XY DSD. Known causative genes for 46,XY DSD include *ATRX*, *CBX2*, *DHH*, *DMRT1*, *GATA4*, *MAP3K1*, *NR0B1* (alias *DAX1*), *NR5A1* (alias *SF1*), *RSPO1*, *SOX9*, *SRY*, *WNT4*, and *WT1* involved in testicular development; *AKR1C2/4*, *AR*, *CYP11A1*, *CYP17A1*, *LHCGR*, *HSD3B2*, *HSD17B3*, *POR*, *SRD5A2*, and *STAR* involved in androgen production or function; and *AMH*, *AMHR2*, *INSL3*, *RXFP2*, and the *HOXD* cluster involved in genital organ formation \[[@CR1],[@CR3],[@CR4]\]. In addition, various chromosomal rearrangements have also been associated with 46,XY DSD \[[@CR1],[@CR3]\]. However, mutations in known causative genes and cytogenetically detectable chromosomal rearrangements have been identified in only 20% to 30% of cases \[[@CR1]\], indicating that other genetic or environmental factors play an important role in the development of 46,XY DSD.

Recent advances in molecular technology, including array-based comparative genomic hybridization (aCGH), multiplex ligation-dependent probe amplification (MLPA), and next-generation sequencing (NGS), have enabled high-throughput analysis of clinical samples. Of these, aCGH is highly useful to detect copy-number variations (CNVs) in the genome of individuals with apparently normal karyotypes \[[@CR5],[@CR6]\], and MLPA can identify various copy-number alterations in specific disease-associated loci \[[@CR7]\]. NGS primarily focuses on identification of nucleotide substitutions. Molecular cytogenetic analyses using aCGH or MLPA revealed the importance of CNVs as the cause of several genetic disorders, although accumulating evidence shows that submicroscopic CNVs can also occur as functionally neutral polymorphisms \[[@CR6]\]. Here, we review recent reports on molecular cytogenetic analyses of patients with 46,XY DSD.

Findings {#Sec1}
========

46,XY DSD-associated CNVs identified by molecular cytogenetic analyses {#Sec3}
----------------------------------------------------------------------

In this review, we summarize the results of 15 recent studies \[[@CR8]-[@CR22]\]. We found these papers through a PubMed search using the key words 'disorders of sex development', together with 'comparative genomic hybridization', 'multiplex ligation-dependent probe amplification', or 'copy-number variations'. We focused on original articles, in which aCGH or MLPA was used to identify submicroscopic CNVs in patients with 46,XY DSD. The 15 studies showed 28 deletions and 4 duplications as genetic causes of 46,XY DSD, as well as several other CNVs whose association with the disease phenotype remains uncertain (Table [1](#Tab1){ref-type="table"}, parts a and b, and Table [2](#Tab2){ref-type="table"}) \[[@CR8]-[@CR22]\]. Notably, White et al. identified pathogenic CNVs in 3 of 23 patients with 46,XY gonadal dysgenesis \[[@CR18]\], and Igarashi et al. detected CNVs in 3 of 24 patients with various types of 46,XY DSD \[[@CR9]\]. These data suggest the significance of submicroscopic CNVs in the etiology of 46,XY DSD. All CNVs, except for those on the sex chromosomes, were detected in the heterozygous state. Parental samples of the CNV-positive patients were analyzed in some cases, confirming the *de novo* occurrence or maternal inheritance of all CNVs examined (Table [1](#Tab1){ref-type="table"}, parts a and b).Table 1**46,XY DSD-associated deletions identified by molecular cytogenetic analysesCase/familyPatientSize of deletionLocusAffected DSD-causative genesGonadal phenotypeExternal genitaliaAdditional clinical featuresMethodInheritanceReference**a) Deletions encompassing known 46,XY DSD-causative genesCase 174 kb2p16.3*LHCGR*Testes with rete testis, epididymic structures, residual adrenal structuresAmbiguous genitaliaN.D.aCGH*De novo*Richard et al. \[[@CR8]\]Case 28.5 Mb9p24.1-p24.3*DMRT1*Streak gonads with ovarian ductsFemaleMR, schizophreniaaCGHN.D.Igarashi et al. \[[@CR9]\]Case 310.6 Mb9p23-p24.3*DMRT1*PGD with dysgerminomaClitoromegaryMild MRaCGHN.E.Ledig et al. \[[@CR10]\]Case 49.7 Mb9p23-p24.3*DMRT1*GDN.D.Hydrops, facial dysmorphism, limb and kidney abnormalitiesaCGH*De novo*Ledig et al. \[[@CR10]\]Case 5821.6 kb9p24.3*DMRT1*CGDFemaleNoneaCGHN.E.Ledig et al. \[[@CR10]\]Case 6103.2 kb9p24.3*DMRT1*CGDFemaleNoneaCGHN.E.Ledig et al. \[[@CR10]\]Case 79.7 Mb/duplication (26 Mb)9p23-p24.3/9p13.1-p23*DMRT1*GDN.D.NoneTargeted aCGH*De novo*Tannour-Louet et al. \[[@CR11]\]Case 86.7 Mb9p24.1-pter*DMRT1*GDN.D.NoneTargeted aCGH*De novo*Tannour-Louet et al. \[[@CR11]\]Case 90.26 Mb9p24.3*DMRT1*CGDN.D.NoneTargeted aCGHN.D.Tannour-Louet et al. \[[@CR11]\]Case 100.20 Mb9p24.3*DMRT1*GDN.D.NoneTargeted aCGHN.E.Tannour-Louet et al. \[[@CR11]\]Case 110.24 Mb9q33.3*NR5A1* (*SF1*)Abnormal germ cells, no Leydig cellsAmbiguous genitaliaN.D.aCGHMaternalHarrison et al. \[[@CR12]\]Case 123.1 to 4.8 kb9q33.3*NR5A1* (*SF1*)Leydig cell hyperplasia, scarce germ cells, carcinoma *in situ*Female without uterus, clitoromegalyN.D.Custom MLPAN.D.Barbaro et al. \[[@CR13]\]Case 130.96 Mb9q33.3*NR5A1* (*SF1*)N.D.Clitoromegaly, shallow vaginal entrancePtosisaCGH*De novo*van Silfhout et al. 2009 \[[@CR14]\]Case 141.54 Mb9q33.3*NR5A1* (*SF1*)N.E.FemaleMild MR, minor dysmorphismsaCGH*De novo*Brandt et al. \[[@CR15]\]Case 153.07 Mb9q33.3-q34.11*NR5A1* (*SF1*)OvotestisClitoromegalyGenitopatellar syndromeaCGHN.D.Schlaubitz et al. \[[@CR16]\]Case 1610 Mb11p12-p14.1*WT1*N.E.FemaleWAGR syndrome^a^aCGH*De novo*Le Caignec et al. \[[@CR17]\]Case 1718.0 Mb2q31.1-q32.1*HOXD* clusterN.D.Severe micropenis, hypospadiasShort stature, MR, multiple anomaliesaCGHN.D.Igarashi et al. \[[@CR9]\]Case 18503.2 kbYq11.223AZFb-c regionCGDFemaleNoneaCGHN.D.Ledig et al. \[[@CR10]\]b) Deletions in the upstream region of known 46,XY DSD-causative genesCase 191.193 Mb17q24.2-q24.3Upstream of SOX9CGDFemaleCleft palate, short statureSNP arrayN.D.White et al. \[[@CR18]\]Case 203.3 Mb17q24.2-q24.3Upstream of SOX9CGDFemaleAcampomelic campomelic dysplasia, kyphoscoliosisaCGHN.D.Ledig et al. \[[@CR10]\]Family 1Proband240 kb17q24.3Upstream of SOX9Small testis (right), streak gonad (left)Asymmetric external genitalia, urogenital sinus with a phallusNoneMLPA/aCGHMaternalBenko et al. \[[@CR19]\]Family 1Cousin240 kb17q24.3Upstream of SOX9Streak gonad with gonadoblastoma (right), ovary (left)FemaleNoneMLPA/aCGHMaternalBenko et al. \[[@CR19]\]Case 21236.3 kb17q24.3Upstream of SOX9Streak gonad (right), gonadal tumor (left)FemaleNoneMLPA/aCGHMaternalKim et al. \[[@CR20]\]Family 2Proband65.4 kb17q24.3Upstream of SOX9Dysgenic testis^b^Ambiguous genitaliaNoneMLPA/aCGHMaternalKim et al. \[[@CR20]\]Family 2Sibling65.4 kb17q24.3Upstream of SOX9Dysgerminoma (right), streak gonad with a gonadoblastoma (left)FemaleNoneMLPA/aCGHMaternalKim et al. \[[@CR20]\]Family 3Proband136 kb17q24.3Upstream of SOX9Dysgenic gonad with a gonadoblastomaFemaleN.D.MLPA/aCGHMaternalKim et al. \[[@CR20]\]Family 3Maternal relative136 kb17q24.3Upstream of SOX9Ovarian dysgerminomaFemaleN.D.MLPA/aCGHMaternalKim et al. \[[@CR20]\]Family 4Proband576.9 kb17q24.3Upstream of SOX9CGDFemaleNoneMLPA/aCGHMaternalKim et al. \[[@CR20]\]Family 4Sibling576.9 kb17q24.3Upstream of SOX9CGDFemaleNoneMLPA/aCGHMaternalKim et al. \[[@CR20]\]Case 2235 kb8p23.1Upstream of GATA4CGDFemaleAdrenal hypoplasia congenitaSNP arrayN.D.White et al. \[[@CR18]\]Case 230.22 Mb8p23.1Upstream of GATA4PGDAmbiguous genitaliaN.D.aCGHMaternalHarrison et al. \[[@CR12]\]Case 24257 kbXp21.2Upstream of NR0B1 (DAX1)Testis-like (right), streak gonad (left)FemaleNoneaCGHMaternalSmyk et al. \[[@CR21]\]DSD, disorders of sex development; PGD, partial gonadal dysgenesis; CGD, complete gonadal dysgenesis; GD, gonadal dysgenesis of unknown severity; N.E., not examined; N.D., not described; MR, mental retardation; aCGH, array-based comparative genomic hybridization; MLPA, multiplex ligation-dependent probe amplification. ^a^Wilms tumor, aniridia, genitourinary anomalies, and mental retardation syndrome. ^b^Dysgenic testis with remnants of ducti deferentes and rete testis and with primitive seminiferous tubules.Table 2**46,XY DSD-associated duplications identified by molecular cytogenetic analysesCaseSize of duplicationLocusAffected DSD-causative geneGonadal phenotypeExternal genitaliaOther clinical featuresMethodReference**Case 116.23 MbXp21.1-p22.2*NR0B1* (*DAX1*)CGDFemaleIUGR, facial dysmorphism, disturbance of pulmonary adaption, muscular hypertonia, hearing defect, mental retardation, short stature, macrocephalyaCGHLedig et al. \[[@CR10]\]Case 2729 kbXp21.2*NR0B1* (*DAX1*)PGD with testicular residuesClitoromegaryNoneaCGHLedig et al. \[[@CR10]\]Case 3771 kbXp21.2*NR0B1* (*DAX1*)CGDFemaleNoneSNP arrayWhite et al. \[[@CR18]\]Case 4800 kbXp21.2*NR0B1* (*DAX1*)Streak gonad, testicular tissue with atrophic tubules (right)Ambiguous genitaliaN.D.Custom MLPABarbaro et al. \[[@CR22]\]DSD, disorders of sex development; PGD, partial gonadal dysgenesis; CGD, complete gonadal dysgenesis; N.D., not described; MLPA, multiplex ligation-dependent probe amplification; aCGH, array-based comparative genomic hybridization; IUGR, intrauterine growth restriction.

Deletions encompassing known 46,XY DSD-causative genes {#Sec4}
------------------------------------------------------

Submicroscopic deletions encompassing known causative genes were identified in 18 patients (Table [1](#Tab1){ref-type="table"}, part a). These deletions ranged from 74 kb to 18.0 Mb and caused haploinsufficiency of *LHCGR*, *DMRT1*, *NR5A1*, *WT1*, or *HOXD* cluster \[[@CR8]-[@CR17]\]. Of these deletions, those encompassing *DMRT1* or *NR5A1* were relatively common. Notably, CNVs in cases 3, 16, and 17 were 10 to 18 Mb in length. These results imply that in some cases, deletions ≥10 Mb can be missed by standard karyotyping, although this method is expected to detect CNVs ≥5 to 10 Mb \[[@CR11]\]. Actually, the results of karyotyping are affected by the quality of samples and the genomic position of CNVs \[[@CR11]\]. Submicroscopic deletions in the 18 patients were associated with both isolated and syndromic 46,XY DSD. Syndromic DSD resulting from these deletions were primarily ascribed to contiguous gene deletions. For example, a deletion in case 16 encompassing *WT1* and *PAX6* caused 46,XY DSD, Wilms tumor, aniridia, and mental retardation, which is collectively referred to as WAGR syndrome. This WAGR syndrome has been described in several patients with cytogenetically detectable deletions at 11p. The size of submicroscopic deletions in 18 patients roughly corresponded to patients' phenotypes (isolated or syndromic); 7 of the 9 patients with deletions ≥1.0 Mb manifested additional clinical features such as mental retardation, short stature, and facial dysmorphism, whereas such features were not reported in 9 patients with smaller deletions (Table [1](#Tab1){ref-type="table"}, part a). On the other hand, syndromic 46,XY DSD was also caused by deletions of a single gene with complex functions. Indeed, finger anomalies observed in DSD patients with *HOXD* cluster-containing deletions are consistent with the fact that *HOXD* genes, particularly *HOXD13* \[[@CR23]\], control the development of limb and external genitalia \[[@CR4]\]. Although submicroscopic deletions involving known causative genes were frequently identified in patients with syndromic 46,XY DSD (Table [1](#Tab1){ref-type="table"}, part a), previous molecular cytogenetic analyses may be biased toward patients with complex phenotypes. Thus, further studies are necessary to clarify the precise frequency of pathogenic CNVs in patients with isolated and syndromic 46,XY DSD.

Deletions in the upstream regions of known 46,XY DSD-causative genes {#Sec5}
--------------------------------------------------------------------

Submicroscopic deletions that reside adjacent to known causative genes also underlie 46,XY DSD. To date, deletions involving the upstream regions of *SOX9*, *GATA4*, or *NR0B1* have been reported to cause 46,XY gonadal dysgenesis (Table [1](#Tab1){ref-type="table"}, part b) \[[@CR10],[@CR12],[@CR18]-[@CR21]\]. These deletions are predicted to disrupt the cis-regulatory machinery of genes involved in testis formation. For example, SOX9 is regulated by SRY and plays a critical role in the development of testis and long bones \[[@CR1]\]. *SOX9* abnormalities lead to 46,XY gonadal dysgenesis with or without campomelic dysplasia \[[@CR1]\]. It is known that *SOX9* expression is tightly regulated by multiple cis-acting enhancers in the upstream and downstream regions and that elimination of the enhancer(s) leads to tissue-specific dysregulation of *SOX9* \[[@CR10],[@CR18]-[@CR20]\]. Previous studies have mapped *SOX9* enhancers for craniofacial tissues to a genomic interval \>1.0 Mb apart from the coding region and a testis enhancer to a 32.5-kb region at a position 607 to 640 kb upstream from the start codon \[[@CR10],[@CR18]-[@CR20]\]. These enhancer regions seem to contain transcription factor binding sites which are essential to maintain *SOX9* expression during development. Since microdeletions in the *SOX9* upstream region can result in complete gonadal dysgenesis similar to that observed in patients with *SOX9* amorphic mutations, elimination of the distal enhancer seems to completely abolish *SOX9* expression on the affected allele \[[@CR10],[@CR18]-[@CR20]\]. Deletions in the upstream regions of *GATA4* and *NR0B1* are also likely to encompass cis-acting enhancers of these genes \[[@CR12],[@CR18],[@CR21]\]. Identification of deletions in the upstream or downstream regions of genes provides clues regarding cis-regulatory mechanisms of each gene.

Duplications encompassing known 46,XY DSD-causative genes {#Sec6}
---------------------------------------------------------

Submicroscopic duplications involving *NR0B1* were identified in several patients with 46,XY DSD (Table [2](#Tab2){ref-type="table"}) \[[@CR10],[@CR18],[@CR22]\]. *NR0B1* is a transcription factor gene isolated from the dosage-sensitive sex reversal adrenal hypoplasia congenita critical region on Xp21 \[[@CR24]\]. Overdosage of *NR0B1* is a well-known cause of syndromic 46,XY DSD in individuals with large X chromosomal rearrangements \[[@CR25]\]. Recently, molecular cytogenetic analysis by Smyk et al. has shown that submicroscopic duplications encompassing *NR0B1* can lead to 46,XY DSD as a sole clinical manifestation \[[@CR21]\]. Copy-number gains of *NR0B1* were predicted to perturb testicular development by downregulating the protein expression of SF1, WT1, and SOX9 \[[@CR18]\].

CNVs of unknown pathogenicity {#Sec7}
-----------------------------

Genome-wide copy-number analyses identified several submicroscopic CNVs that could be associated with the development of 46,XY DSD. Ledig et al. performed aCGH analysis on 87 patients with 46,XY DSD and identified 31 CNVs which have not been described as polymorphisms \[[@CR10]\]. While 7 of the 31 CNVs encompassed known DSD-causative genes, the other CNVs have not been implicated in DSD. Ledig et al. proposed that several genes, including *GKAP1*, *NCOA4*, and *CTNNA3*, are novel candidate genes for 46,XY DSD. Furthermore, Tannour-Louet et al. \[[@CR11]\] analyzed 116 patients with 46,XY and 46,XX DSD and 8,951 control individuals, and identified 25 CNVs that may underlie DSD. Of these, 13 CNVs were detected in individuals with 46,XY karyotype. Further studies on large cohorts will clarify the pathogenicity of these CNVs.

Clinical applications of molecular cytogenetic technologies {#Sec8}
-----------------------------------------------------------

Molecular cytogenetic analyses using aCGH or MLPA would be beneficial for patients with 46,XY DSD, because identification of pathogenic CNVs could help to predict the disease outcome and possible complications of patients. For example, patients with deletions encompassing *WT1* have a high risk of Wilms tumor and renal failure. Furthermore, detection of disease-associated CNVs significantly improves the accuracy of genetic counseling for patients' families. Molecular cytogenetic analyses, together with mutation screening using NGS, should be included in the diagnostic workup of patients with 46,XY DSD of unknown origin.

Summary and conclusions {#Sec9}
-----------------------

Recent studies revealed that submicroscopic CNVs constitute a fraction of the genetic causes of both isolated and syndromic 46,XY DSD. ACGH and MLPA appear to be useful for molecular diagnosis of patients with 46,XY DSD. Furthermore, genome-wide copy-number analyses using aCGH will serve to identify novel causes of 46,XY DSD.

aCGH

:   array-based comparative genomic hybridization

CNV

:   copy-number variation

DSD

:   disorders of sex development

MLPA

:   multiplex ligation-dependent probe amplification
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